SEOUL - South Korea has become the fifth market for AstraZeneca PLC's first-in-class lung cancer drug Tagrisso (osimertinib) after the US, Europe, Japan and Israel, following approval by the Ministry of Food and Drug Safety for EGFR T790M mutation-positive progressive locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who have undergone EGFR-TKI therapy.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?